TGFB1 and prostate carcinoma: In this study, we further used the CRISPR/Cas9 genome-editing technique to generate a dominant-negative mutation of the cognate TGF-β receptor type II (TGFBRII) that is capable of attenuating TGF-β signal transduction in castration-resistant DU145 prostate cancer cells.